ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts [Seeking Alpha]
ArriVent BioPharma, Inc. (AVBP)
Company Research
Source: Seeking Alpha
Firmonertinib has continued to deliver encouraging efficacy with a tolerable safety profile across treated patients. Under conservative assumptions, there is an asymmetric valuation setup. With a solid cash runway and an industry facing an unprecedented patent cliff, AVBP is well-positioned both as a standalone asset and as a potential M&A candidate. Wirestock/iStock via Getty Images Here at the Lab, we generally do not cover late-stage clinical oncology companies. Still, this time, ArriVent BioPharma ( AVBP ) warrants an exception due to Firmonertinib's near-term catalysts (Fig. 1) and the Chinese asset's origin profile. This remains a This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of AVBP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship wi
Show less
Read more
Impact Snapshot
Event Time:
AVBP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AVBP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AVBP alerts
High impacting ArriVent BioPharma, Inc. news events
Weekly update
A roundup of the hottest topics
AVBP
News
- ArriVent BioPharma (AVBP) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib [Seeking Alpha]Seeking Alpha
- ArriVent BioPharma (AVBP) had its price target raised by B. Riley Financial, Inc. from $37.00 to $45.00. They now have a "buy" rating on the stock.MarketBeat
- ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 [Yahoo! Finance]Yahoo! Finance
AVBP
Earnings
- 3/5/26 - Miss
AVBP
Sec Filings
- 3/17/26 - Form 8-K
- 3/5/26 - Form S-8
- 3/5/26 - Form 10-K
- AVBP's page on the SEC website